Medican Enterprises Appoints Drew Milburn As CEO Of Its U.S. Subsidiary

Medican Enterprises Appoints Drew Milburn As CEO Of Its U.S. Subsidiary

LAS VEGAS--(BUSINESS WIRE)--Medican Enterprises, Inc. has appointed Drew Milburn to the position of Chief Executive Officer of Medican (US) Systems, Inc. (Medican US), a wholly owned subsidiary of Medican Enterprises, Inc. (OTCBB:MDCN).

Medican US was recently formed to pursue business activities in the United States medical and recreational marijuana sectors.

Mr. Milburn has more than 10 years in the marijuana sector. From 2005 to 2008, Mr. Milburn established and implemented manufacturing and marijuana cultivation practices that successfully launched more than 50 separated cultivation facilities in the state of California. He has founded and operated medical cannabis dispensaries and worked closely with caregivers, medical professionals, and government officials of all levels to build safe, high quality and high-grade products and services in more than five states. In 2010, he received the first medical marijuana license issued in Colorado Springs and founded "We Grow", a large medical cannabis dispensary and garden facility in Colorado Springs. He is widely recognized as an expert in the industry and has consulted for businesses, government officials and enforcement agencies in both Canada and the Untied States.

"We are very pleased to have Drew on our team as we seek to identify promising U.S. marijuana business activities," stated Ken Williams, CEO of Medican Enterprises. "Drew's deep knowledge of the industry, combined with his vision and exceptional experience, make him an ideal candidate to spearhead our efforts in the U.S. Drew's appointment demonstrates our commitment to developing and adhering to the highest technical, operational and regulatory standards in the marijuana sector as well as to building a team that has the background necessary to execute on our strategic plan."

Mr. Milburn commented: "After years of watching companies come and go in this sector, I am pleased to be leading Medican's entry into the US market. This is a historic time for the U.S. marijuana industry, and I hope to make Medican a positive part of this exciting national trend. It is great to be working with a group of individuals that understand the complexities of this industry and how important it is to identify, develop and expand credible business opportunities in this space. I look forward to bringing my background to Medican as we seek to establish our U.S. operations and create value for our shareholders."

Medican (US) Systems, Inc., a wholly-owned subsidiary of Medican Enterprises, Inc. (OTCBB:MDCN), was formed to seek investments in commercial real estate which it can lease to marijuana growers in states where growing is legal; to provide dispensary management and professional consulting services to the medical marijuana and recreational marijuana sectors; and to offer a broad range of leasing and financing solutions to dispensaries, kitchens and cultivations centers.

In the United States, 23 states have legalized cannabis for medical use with three more states pending legislation. Washington and Colorado State have legalized marijuana for recreational purposes as well. The legalized marijuana industry in the Untied States is thriving. According to a November 2013 report from ArcView Market Research, the national legal marijuana market in the United States projected to grow from $1.3 billion to 10.2 billion by 2018.

About Medican Enterprises, Inc.
Medican Enterprises is a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, Medican is seeking to invest in our businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada. For more information visit: www.medicaninc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of representatives of Medican Enterprises, Inc. (the "Company") related thereto includes forward-looking statements within the meaning of the U.S. federal securities laws. Forward looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control), which could cause actual results to differ from the forward looking statements. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management but are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company's efforts to establish a business in the U.S. as described herein) may differ from those set forth in the forward-looking statements. Except as required by applicable law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contacts

Medican Enterprises Inc.
Ken Williams, +1.800.416.8802
CEO
[email protected] 

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.